



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

## Lupin Launches Generic Cipro® for Oral Suspension in the US

**Mumbai, Baltimore, June 13, 2014:** Pharma Major Lupin Limited (Lupin) announced today that the company's US subsidiary, Lupin Pharmaceuticals Inc. (LPI) has launched its Ciprofloxacin for Oral Suspension, 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL) in the US having received final approval from the FDA earlier.

Lupin's Ciprofloxacin Oral Suspension, 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500 mg/5 mL) is the generic equivalent of Bayer HealthCare Pharmaceuticals, Inc.'s (Bayer) Cipro® Oral Suspension 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500 mg/5 mL) and indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in various conditions and patient populations.

Lupin is the first applicant to file an ANDA for Cipro® Oral Suspension 250 mg/ml & 500 mg/ml and as such is entitled to 180 days of marketing exclusivity. Cipro® Oral Suspension had annual U.S sales of US\$ 8.6 million (IMS MAT March, 2014).

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 110,866 million (USD 1.83 billion) and Rs. 18,364 million (USD 304 million) respectively. Please visit <http://www.lupinworld.com> for more information.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>

### For more information, please contact -

Shamsher Gorawara  
Head – Corporate Communications  
Ph: +91- 98 20 338 555  
Email: [shamshergorawara@lupinpharma.com](mailto:shamshergorawara@lupinpharma.com)

or

Alpesh Dalal  
Head – M & A and Investor Relations  
Lupin Limited  
Ph: +91 - 98 20 023 511  
Email: [alpeshdlal@lupinpharma.com](mailto:alpeshdlal@lupinpharma.com)

### Safe Harbor Statement

\* CIPRO is a registered trademark of Bayer Aktiengesellschaft.